Y MAbs Net Worth
Y MAbs Net Worth Breakdown | YMAB |
Y MAbs Net Worth Analysis
Y MAbs' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Y MAbs' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Y MAbs' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Y MAbs' net worth analysis. One common approach is to calculate Y MAbs' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Y MAbs' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Y MAbs' net worth. This approach calculates the present value of Y MAbs' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Y MAbs' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Y MAbs' net worth. This involves comparing Y MAbs' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Y MAbs' net worth relative to its peers.
Enterprise Value |
|
To determine if Y MAbs is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Y MAbs' net worth research are outlined below:
| Y mAbs Therapeutics generated a negative expected return over the last 90 days | |
| Y mAbs Therapeutics has high historical volatility and very poor performance | |
| Y mAbs Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 84.82 M. Net Loss for the year was (21.43 M) with profit before overhead, payroll, taxes, and interest of 57.7 M. | |
| Y mAbs Therapeutics currently holds about 133.66 M in cash with (27.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.06. | |
| Roughly 72.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Y-mAbs to Participate at Citis 2024 Global Healthcare Conference |
Y MAbs uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Y mAbs Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Y MAbs' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Y MAbs' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Y MAbs is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Y mAbs Therapeutics backward and forwards among themselves. Y MAbs' institutional investor refers to the entity that pools money to purchase Y MAbs' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Caligan Partners Lp | 2024-06-30 | 582.1 K | Boothbay Fund Management, Llc | 2024-09-30 | 557.4 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 477.7 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 406.3 K | Millennium Management Llc | 2024-06-30 | 349.8 K | Northern Trust Corp | 2024-09-30 | 337.3 K | Charles Schwab Investment Management Inc | 2024-09-30 | 279.6 K | Citadel Advisors Llc | 2024-09-30 | 274.5 K | Connor Clark & Lunn Inv Mgmt Ltd | 2024-06-30 | 176.1 K | Paradigm Biocapital Advisors Lp | 2024-09-30 | 4.1 M | Blackrock Inc | 2024-06-30 | 2.9 M |
Follow Y MAbs' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 533.89 M.Market Cap |
|
Project Y MAbs' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.17) | (0.18) | |
| Return On Capital Employed | (0.24) | (0.25) | |
| Return On Assets | (0.17) | (0.18) | |
| Return On Equity | (0.21) | (0.22) |
When accessing Y MAbs' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Y MAbs' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Y MAbs' profitability and make more informed investment decisions.
Please note, the presentation of Y MAbs' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Y MAbs' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Y MAbs' management manipulating its earnings.
Evaluate Y MAbs' management efficiency
Y mAbs Therapeutics has return on total asset (ROA) of (0.1198) % which means that it has lost $0.1198 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2478) %, meaning that it created substantial loss on money invested by shareholders. Y MAbs' management efficiency ratios could be used to measure how well Y MAbs manages its routine affairs as well as how well it operates its assets and liabilities. As of December 1, 2024, Return On Tangible Assets is expected to decline to -0.18. In addition to that, Return On Capital Employed is expected to decline to -0.25. At present, Y MAbs' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 129.5 M, whereas Other Current Assets are forecasted to decline to about 4.9 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.31 | 2.50 | |
| Tangible Book Value Per Share | 2.25 | 2.48 | |
| Enterprise Value Over EBITDA | (8.59) | (9.02) | |
| Price Book Value Ratio | 2.95 | 2.80 | |
| Enterprise Value Multiple | (8.59) | (9.02) | |
| Price Fair Value | 2.95 | 2.80 | |
| Enterprise Value | 220.4 M | 209.4 M |
Evaluating the management effectiveness of Y MAbs allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The YMAB Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Enterprise Value Revenue 5.5213 | Revenue 84.6 M | Quarterly Revenue Growth (0.1) | Revenue Per Share 1.921 | Return On Equity (0.25) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Y MAbs insiders, such as employees or executives, is commonly permitted as long as it does not rely on Y MAbs' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Y MAbs insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Y MAbs Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 8th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 20th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 8th of July 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Y MAbs Earnings per Share Projection vs Actual
Y MAbs Corporate Management
| Courtney Dugan | Vice Relations | Profile | |
| Susan Smith | Senior Officer | Profile | |
| MBBS MBA | Senior Officer | Profile | |
| Torben MSc | VP Operations | Profile | |
| Sue Smith | VP Officer | Profile |
Already Invested in Y mAbs Therapeutics?
The danger of trading Y mAbs Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Y MAbs is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Y MAbs. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Y mAbs Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Y mAbs Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Y MAbs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Y Mabs Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Y Mabs Therapeutics Stock: Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Y mAbs Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Y MAbs. If investors know YMAB will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Y MAbs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.54) | Revenue Per Share 1.921 | Quarterly Revenue Growth (0.1) | Return On Assets (0.12) | Return On Equity (0.25) |
The market value of Y mAbs Therapeutics is measured differently than its book value, which is the value of YMAB that is recorded on the company's balance sheet. Investors also form their own opinion of Y MAbs' value that differs from its market value or its book value, called intrinsic value, which is Y MAbs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Y MAbs' market value can be influenced by many factors that don't directly affect Y MAbs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Y MAbs' value and its price as these two are different measures arrived at by different means. Investors typically determine if Y MAbs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Y MAbs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.